The Pleiotropic Effects of Excessive Luteinizing Hormone Secretion in Transgenic Mice

 

 Buy Article Permissions and Reprints

ABSTRACT

Luteinizing hormone (LH) is member of the glycoprotein hormone family of gonadotropins, which also includes the highly related human chorionic gonadotropin and follicle-stimulating hormone. The necessity of these factors for sustaining human fertility has been known for decades. In addition, elevated serum levels of LH have been associated with polycystic ovarian syndrome, suggesting that the appropriate balance of LH is critical for maintaining reproductive function. To dissect the biological consequences of aberrant LH signaling in vivo, several genetically engineered mouse models have been developed that overexpress LH or have increased LH signaling. These models underscore the importance of tightly regulated LH levels for normal reproductive function, and reveal novel roles for LH and gonadal hormones in tumorigenesis of multiple tissues, including the ovary, mammary gland, and pituitary. Thus, mice with altered LH signaling provide valuable tools in understanding normal reproduction and various pathological conditions.

REFERENCES

• 1 Stenman U H, Tiitinen A, Alfthan H, Valmu L. The classification, functions and clinical use of different isoforms of HCG.  Hum Reprod Update. 2006;  12 769-784
  CrossrefPubMedGoogle Scholar
• 2 Richards J S. New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells.  Mol Endocrinol. 2001;  15 209-218
  PubMedGoogle Scholar
• 3 Risma K A, Clay C M, Nett T M, Wagner T, Yun J, Nilson J H. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors.  Proc Natl Acad Sci USA. 1995;  92 1322-1326
  CrossrefPubMedGoogle Scholar
• 4 Fares F A, Suganuma N, Nishimori K, LaPolt P S, Hsueh A J, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.  Proc Natl Acad Sci USA. 1992;  89 4304-4308
  PubMedGoogle Scholar
• 5 Rulli S B, Kuorelahti A, Karaer O, Pelliniemi L J, Poutanen M, Huhtaniemi I. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin.  Endocrinology. 2002;  143 4084-4095
  CrossrefPubMedGoogle Scholar
• 6 Rulli S B, Ahtiainen P, Makela S, Toppari J, Poutanen M, Huhtaniemi I. Elevated steroidogenesis, defective reproductive organs, and infertility in transgenic male mice overexpressing human chorionic gonadotropin.  Endocrinology. 2003;  144 4980-4990
  CrossrefPubMedGoogle Scholar
• 7 Matzuk M M, DeMayo F J, Hadsell L A, Kumar T R. Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice.  Biol Reprod. 2003;  69 338-346
  CrossrefPubMedGoogle Scholar
• 8 Lania A, Gangi E, Romoli R et al.. Impaired estrogen-induced negative feedback on gonadotropin secretion in patients with gonadotropin-secreting and nonfunctioning pituitary adenomas.  Eur J Clin Invest. 2002;  32 335-340
  CrossrefPubMedGoogle Scholar
• 9 Morales A J, Laughlin G A, Butzow T, Maheshwari H, Baumann G, Yen S S. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.  J Clin Endocrinol Metab. 1996;  81 2854-2864
  CrossrefPubMedGoogle Scholar
• 10 Couse J F, Yates M M, Walker V R, Korach K S. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta.  Mol Endocrinol. 2003;  17 1039-1053
  CrossrefPubMedGoogle Scholar
• 11 Fisher C R, Graves K H, Parlow A F, Simpson E R. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene.  Proc Natl Acad Sci USA. 1998;  95 6965-6970
  CrossrefPubMedGoogle Scholar
• 12 Britt K L, Drummond A E, Cox V A et al.. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene.  Endocrinology. 2000;  141 2614-2623
  CrossrefPubMedGoogle Scholar
• 13 Meehan T P, Harmon B G, Overcast M E et al.. Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chorionic gonadotropin-lutropin receptor complex.  J Mol Endocrinol. 2005;  34 489-503
  CrossrefPubMedGoogle Scholar
• 14 Risma K A, Hirshfield A N, Nilson J H. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology.  Endocrinology. 1997;  138 3540-3547
  CrossrefPubMedGoogle Scholar
• 15 Flaws J A, Abbud R, Mann R J, Nilson J H, Hirshfield A N. Chronically elevated luteinizing hormone depletes primordial follicles in the mouse ovary.  Biol Reprod. 1997;  57 1233-1237
  CrossrefPubMedGoogle Scholar
• 16 Mann R J, Keri R A, Nilson J H. Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology.  Recent Prog Horm Res. 2003;  58 343-375
  CrossrefPubMedGoogle Scholar
• 17 Hodges C A, Ilagan A, Jennings D, Keri R, Nilson J, Hunt P A. Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation.  Hum Reprod. 2002;  17 1171-1180
  CrossrefPubMedGoogle Scholar
• 18 Mann R J, Keri R A, Nilson J H. Transgenic mice with chronically elevated luteinizing hormone are infertile due to anovulation, defects in uterine receptivity, and midgestation pregnancy failure.  Endocrinology. 1999;  140 2592-2601
  CrossrefPubMedGoogle Scholar
• 19 Giudice L C. Endometrium in PCOS: Implantation and predisposition to endocrine CA.  Best Pract Res Clin Endocrinol Metab. 2006;  20 235-244
  CrossrefPubMedGoogle Scholar
• 20 Couse J F, Yates M M, Sanford R, Nyska A, Nilson J H, Korach K S. Formation of cystic ovarian follicles associated with elevated luteinizing hormone requires estrogen receptor-beta.  Endocrinology. 2004;  145 4693-4702
  CrossrefPubMedGoogle Scholar
• 21 Keri R A, Lozada K L, Abdul-Karim F W, Nadeau J H, Nilson J H. Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition.  Proc Natl Acad Sci USA. 2000;  97 383-387
  CrossrefPubMedGoogle Scholar
• 22 Schomberg D W, Couse J F, Mukherjee A et al.. Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult.  Endocrinology. 1999;  140 2733-2744
  CrossrefPubMedGoogle Scholar
• 23 Couse J F, Bunch D O, Lindzey J, Schomberg D W, Korach K S. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse.  Endocrinology. 1999;  140 5855-5865
  CrossrefPubMedGoogle Scholar
• 24 Couse J F, Hewitt S C, Bunch D O et al.. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta.  Science. 1999;  286 2328-2331
  CrossrefPubMedGoogle Scholar
• 25 Owens G E, Keri R A, Nilson J H. Ovulatory surges of human CG prevent hormone-induced granulosa cell tumor formation leading to the identification of tumor-associated changes in the transcriptome.  Mol Endocrinol. 2002;  16 1230-1242
  CrossrefPubMedGoogle Scholar
• 26 Burger H G. The endocrinology of the menopause.  Maturitas. 1996;  23 129-136
  CrossrefPubMedGoogle Scholar
• 27 Hsieh M, Mulders S M, Friis R R, Dharmarajan A, Richards J S. Expression and localization of secreted frizzled-related protein-4 in the rodent ovary: evidence for selective up-regulation in luteinized granulosa cells.  Endocrinology. 2003;  144 4597-4606
  CrossrefPubMedGoogle Scholar
• 28 Kero J, Poutanen M, Zhang F P et al.. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex.  J Clin Invest. 2000;  105 633-641
  PubMedGoogle Scholar
• 29 Milliken E L, Ameduri R K, Landis M D, Behrooz A, Abdul-Karim F W, Keri R A. Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice.  Endocrinology. 2002;  143 3671-3680
  CrossrefPubMedGoogle Scholar
• 30 Milliken E L, Zhang X, Flask C, Duerk J L, MacDonald P N, Keri R A. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.  Cancer Lett. 2005;  229 205-215
  CrossrefPubMedGoogle Scholar
• 31 Berger U, Wilson P, McClelland R A et al.. Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer.  Cancer Res. 1987;  47 6793-6799
  PubMedGoogle Scholar
• 32 Chouvet C, Vicard E, Devonec M, Saez S. 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20).  J Steroid Biochem. 1986;  24 373-376
  CrossrefPubMedGoogle Scholar
• 33 Simboli-Campbell M, Narvaez C J, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells.  J Steroid Biochem Mol Biol. 1996;  58 367-376
  CrossrefPubMedGoogle Scholar
• 34 Zinser G, Packman K, Welsh J. Vitamin D(3) receptor ablation alters mammary gland morphogenesis.  Development. 2002;  129 3067-3076
  PubMedGoogle Scholar
• 35 Mohammad H P, Abbud R A, Parlow A F, Lewin J S, Nilson J H. Targeted overexpression of luteinizing hormone causes ovary-dependent functional adenomas restricted to cells of the Pit-1 lineage.  Endocrinology. 2003;  144 4626-4636
  CrossrefPubMedGoogle Scholar
• 36 Mohammad H P, Seachrist D D, Quirk C C, Nilson J H. Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone.  Mol Endocrinol. 2004;  18 2583-2593
  CrossrefPubMedGoogle Scholar
• 37 Kero J T, Savontaus E, Mikola M et al.. Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion.  Am J Physiol Endocrinol Metab. 2003;  285 E812-E818
  PubMedGoogle Scholar
• 38 Shibli-Rahhal A, Van Beek M, Schlechte J A. Cushing's syndrome.  Clin Dermatol. 2006;  24 260-265
  PubMedGoogle Scholar
• 39 Chang R J. A practical approach to the diagnosis of polycystic ovary syndrome.  Am J Obstet Gynecol. 2004;  191 713-717
  CrossrefPubMedGoogle Scholar
• 40 Ahtiainen P, Rulli S B, Shariatmadari R et al.. Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice.  Oncogene. 2005;  24 7301-7309
  CrossrefPubMedGoogle Scholar
• 41 Liu G, Duranteau L, Carel J C, Monroe J, Doyle D A, Shenker A. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor.  N Engl J Med. 1999;  341 1731-1736
  CrossrefPubMedGoogle Scholar
• 42 Richter-Unruh A, Wessels H T, Menken U et al.. Male LH-independent sexual precocity in a 3.5-year-old boy caused by a somatic activating mutation of the LH receptor in a Leydig cell tumor.  J Clin Endocrinol Metab. 2002;  87 1052-1056
  CrossrefPubMedGoogle Scholar
• 43 Yarram S J, Perry M J, Christopher T J et al.. Luteinizing hormone receptor knockout (LuRKO) mice and transgenic human chorionic gonadotropin (hCG)-overexpressing mice (hCG alphabeta + ) have bone phenotypes.  Endocrinology. 2003;  144 3555-3564
  CrossrefPubMedGoogle Scholar
• 44 Riggs B L, Khosla S, Melton III L J. Sex steroids and the construction and conservation of the adult skeleton.  Endocr Rev. 2002;  23 279-302
  CrossrefPubMedGoogle Scholar
• 45 Lubahn D B, Moyer J S, Golding T S, Couse J F, Korach K S, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.  Proc Natl Acad Sci USA. 1993;  90 11162-11166
  CrossrefPubMedGoogle Scholar

Ruth A KeriPh.D. 

Department of Pharmacology, Case Western Reserve University, School of Medicine

10900 Euclid Avenue, Cleveland, OH 44106-4965

Email: keri@case.edu